Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
399.2 USD | +0.82% | +6.68% | +30.94% |
Apr. 24 | Baird Adjusts Medpace Price Target to $454 From $446, Maintains Outperform Rating | MT |
Apr. 23 | Transcript : Medpace Holdings, Inc., Q1 2024 Earnings Call, Apr 23, 2024 |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 53% by 2026.
- The company returns high margins, thereby supporting business profitability.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 35.42 times its estimated earnings per share for the ongoing year.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The valuation of the company is particularly high given the cash flows generated by its activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+30.94% | 12.24B | C+ | ||
+2.60% | 42.75B | B | ||
+47.70% | 41.61B | A | ||
+12.06% | 41.34B | B- | ||
-8.83% | 26.59B | C | ||
+7.72% | 25.49B | B- | ||
-22.78% | 18.12B | B | ||
-1.71% | 11.76B | C+ | ||
+9.50% | 11B | B+ | ||
-15.49% | 10.07B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- MEDP Stock
- Ratings Medpace Holdings, Inc.